LLY
Eli Lilly and Company
LLY has the edge over OUST overall, supported by lower modeled downside and stronger fundamentals.
OUST
Ouster, Inc.
OUST's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OUST Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
OUST's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
OUST PE Valuation
OUST has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
OUST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect OUST's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over OUST on earnings quality, reporting a profit while its opponent remains loss making.
OUST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.65 | +$0.98 |
| Q2 2026 | -$0.82 | +$0.98 |
| Q1 2026 | -$0.93 | +$1.02 |
| Q4 2025 | -$1.07 | +$1.01 |
| Q3 2025 | -$1.63 | +$0.98 |
| Q2 2025 | -$1.80 | +$1.16 |
| Q1 2025 | -$1.95 | +$3.67 |
| Q4 2024 | -$2.08 | +$9.02 |
OUST is still losing money, but far less than before: $0.65 per share over the past year, against $40.12 at its worst in late 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over OUST on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over OUST on profitability, with a higher operating margin.
OUST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $59.3M | +50% |
| Q2 2026 | $54.6M | +56% |
| Q1 2026 | $48.6M | +49% |
| Q4 2025 | $62.2M | +107% |
| Q3 2025 | $39.5M | +41% |
| Q2 2025 | $35M | +30% |
| Q1 2025 | $32.6M | +26% |
| Q4 2024 | $30.1M | +23% |
OUST's revenue has grown year over year for 15 quarters in a row: $59M last quarter, up 50% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -32% | +29 points |
| Q2 2026 | -37% | +40 points |
| Q1 2026 | -40% | +34 points |
| Q4 2025 | 1.4% | +87 points |
| Q3 2025 | -61% | +37 points |
| Q2 2025 | -77% | +17 points |
| Q1 2025 | -73% | +27 points |
| Q4 2024 | -85% | +68 points |
OUST's operating margin was −32% last quarter, up 29 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over OUST on cash generation, producing positive trailing cash flow while its opponent burns cash.
OUST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$35M | -$15M |
| Q2 2026 | -$15.4M | -$13.2M |
| Q1 2026 | -$9.8M | -$4.4M |
| Q4 2025 | -$37.2M | -$33.2M |
| Q3 2025 | -$20M | -$15.7M |
| Q2 2025 | -$2.2M | +$19.8M |
| Q1 2025 | -$5.4M | +$1.7M |
| Q4 2024 | -$4M | +$20.6M |
OUST has burned cash in almost every quarter: −$97M over the past year, against −$32M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over OUST on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
OUST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.3% | +5.5M shares |
| 1 year | +23% | +13.5M shares |
| 3 years | +82% | +32.2M shares |
| 5 years | +1183% | +65.9M shares |
| Available history | +6407% | +70.4M shares |
OUST has 71M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $1,000 |
| Q3 2022 | $3,000 |
| Q2 2022 | $12,000 |
| Q1 2022 | $31,000 |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OUST Net Leverage
OUST's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OUST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.2 | Neutral |
| Stochastic | 26.0 | Neutral |
OUST's weekly RSI is 51 (neutral) and its Stochastic is 26 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OUST PE vs Technology Sector
OUST has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over OUST on trend strength, trading above more of its moving averages.
OUST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.9 | 1.9% above |
| 20 week MA | $38.1 | 4% below |
| 50 week MA | $31.3 | 17% above |
| 100 week MA | $24.9 | 47% above |
| 200 week MA | $16.3 | 125% above |
OUST's trend is mixed: it's above four of its five weekly moving averages, and 125% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
OUST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $97.0 | $162.5 | +68% |
| 2021 | $162.5 | $53.8 | -67% |
| 2022 | $53.8 | $8.88 | -83% |
| 2023 | $8.88 | $7.67 | -14% |
| 2024 | $7.67 | $12.5 | +63% |
| 2025 | $12.5 | $22.0 | +76% |
| 2026 YTD | $22.0 | $36.6 | +67% |
OUST has the edge over LLY on returns for 2026, with the stronger performance.